Hillhurst Biopharmaceuticals, based in Montrose, United States, focuses on developing therapeutic low-dose carbon monoxide technology to combat inflammatory diseases and sickle cell disease. Their innovative medicines target the protective cellular metabolic system of heme oxygenase, hypothesized to reduce inflammation, prevent cell death, and stop hemoglobin polymerization in sickle cell disease. This approach leverages the potential efficacy of carbon monoxide in a commercially feasible manner.

Hillhurst Biopharmaceuticals has made significant strides, including receiving an NIH Heal Initiative Award for their work in pain management and $3 million in NIH SBIR funding for a Phase 2a clinical study in sickle cell disease. These achievements underscore their impact and potential in transforming treatment paradigms for inflammatory and hematologic conditions.